MCF2L

Across TCGA pan-cancer cohorts, MCF2L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MCF2L data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MCF2L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MCF2L expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where MCF2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.881	0.628	.001	35	view →
CCRCC	DFS	Tertile	III,IV	0.789	0.331	.001	30	view →
LUAD	OS	Quartile	II,III,IV	0.190	0.862	.001	11	view →
GBM	OS	Median	All	0.362	0.675	.003	7	view →
LSCC	DFS	Quartile	All	1.000	0.533	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MCF2L–PDAC (DFS)

Open the PDAC breakdown →